Cambridge Healthtech Institute's 8th Annual

Optimizing Protein Expression

( タンパク質発現の最適化 )

発現系の強化

2018年5月2-3日 | World Trade Center | マサチューセッツ州ボストン

 

The 8th annual Optimizing Protein Expression conference delves into protein expression by examining and enhancing expression systems, including CHO, and other mammalian systems, E. coli, yeast, and baculovirus. This conference poses the question: 'What is the best expression system to use to fulfill a project's goals?,' while staying within budget and adhering to project timelines. Experts will share case studies and disclose data, while divulging details of these systems' underlying mechanisms. Comparing and contrasting systems will also be featured to increase understanding in the quest for greater productivity.

Final Agenda

Recommended Short Course(s)*

SC12: Transient Protein Production in Mammalian Cells

Richard Altman, MS, Scientist, Protein Technologies, Amgen

Henry C. Chiou, PhD, Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific


*Separate registration required.

5月2日 (水)

7:30 am Registration and Morning Coffee

タンパク質発現についての画期的な戦略

8:30 Chairperson's Remarks

Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine


8:40 KEYNOTE PRESENTATION: Manufacturing as a Key Value Driver in Biopharmaceuticals

Jorg_ThommesJorg Thommes, PhD, Senior Vice President, Pharmaceutical Sciences & Technology, Visterra, Inc.

A robust manufacturing platform for recombinant protein and antibody manufacturing has emerged over the past decade, which has substantially increased productivity and operational reliability. Thus, manufacturing has matured from a "necessary evil" to a true value driver in biopharmaceutical operations. In this presentation, we will discuss the current state of protein drug manufacturing but also review new frontiers in this field, e.g., further industrialization of antibody manufacturing, accelerated manufacturing for early clinical testing, and manufacturing for new therapeutic modalities.

9:10 Implementation of New Strategies During Early Development of Innovative Therapeutic Molecules

Nicola_BeaucampNicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH

More than 80% of large molecules developed in Roche pRED are novel and complex antibody formats. To minimize timelines and deliver requested quantity and quality, many innovative approaches with respect to throughput, automation and cell culture techniques were taken. These techniques were implemented to support delivery of differentiated molecules based on Roche's strategy on engineering technologies to patients. Technical challenges faced and how they were successfully solved will be presented by case studies.

9:40 Revolution or Evolution - Optimizing Protein Expression Platforms to Support Preclinical Research at AstraZenca

Robert_RothRobert Roth, PhD, Associate Principal Scientist, Innovative Medicines, Discovery Sciences, AstraZeneca

An overview of how AstraZeneca have refined and developed our protein expression platforms to supply reagents to support research across a diverse portfolio. Using specific examples to illustrate how challenges have been resolved through internal development efforts, collaborations with academic partners and technology providers. How do we approach a future where targets are increasingly complex and require bespoke solutions to identify and express proteins that are physiologically relevant?

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

生産性を高める最先端の技術

10:55 The Utilization of mRNA for Transient Transfection in Mid-Scale Protein Production

Anne_LondonAnne Serdakowski London, PhD, Lab Head, Mid-Scale Mammalian Production, Therapeutic Protein Sciences, Novartis Institutes for Biomedical Research

In the biotherapeutic drug discovery process, proteins are often produced quickly in mammalian cell culture systems using transient transfection of DNA. With the intention of producing protein faster by bypassing the transcription process, here we investigate the feasibility of using mRNA as a transfection reagent and aim to identify optimized transfection conditions using a DOE approach. We report statistically significant data which correlates the effect of multiple factors on protein expression level.

11:25 A Versatile Platform for Biologics Research Protein Reagent Generation

Bernd_VoedischBernd Voedisch, PhD, Lab Head and Investigator III, NIBR Biologics Center, Novartis Institutes for Biomedical Research

During the early phases of Biologics research projects, it is necessary to produce a plethora of high quality protein reagents and recombinant cell lines in order to enable generation, screening, and in-depth characterization of therapeutic antibody candidates. The presentation will highlight various challenges in this context, and how these challenges were overcome by applying cutting-edge technologies (e.g., cell line engineering using CRISPR/Cas9 or transposases) in order to lay the foundation for successful Biologics discovery.

11:55 MultiBac: From Protein Complex Structures to Synthetic Viral Nanosystems

Imre_BergerImre Berger, PhD, Professor and Wellcome Trust Senior Investigator, Biochemistry, Biomedical Sciences and BrisSynBio Centre, University of Bristol

The MultiBac BEVS was conceived as a user-friendly tool-kit for producing multiprotein complexes for structural biology, and enabled structure determination of many molecular machines, including previously inaccessible high-value drug targets. More recently, MultiBac developments focus on customized baculoviral genomes tailored for specific applications, such as synthesizing artificial proteins by genetic code expansion, and DNA delivery in mammalian cells and tissues for CRISPR/Cas9-mediated gene editing. Some of these developments will be presented.

 

12:25 pm Presentation to be Announced

 

12:55 Luncheon Presentation I to be Announced

 

1:25 Luncheon Presentation II to be Announced

1:55 Session Break

CHO細胞の発現

2:10 Chairperson's Remarks

Bernd Voedisch, PhD, Lab Head and Investigator III, NIBR Biologics Center, Novartis Institutes for Biomedical Research

2:15 The Application of Next-Generation Sequencing to Understand CHO Cell Biology

Colin_ClarkeColin Clarke, PhD, Principal Investigator, National Institute for Bioprocessing Research and Training (NIBRT)

The publication of genome sequences for CHO cell lines has facilitated study of these cell factories with unprecedented resolution. Our understanding of the CHO cell transcriptome, in particular, has rapidly advanced through the application of next-generation sequencing (NGS) technology to characterize RNA expression (RNA-Seq). In this talk, I will present examples of how RNASeq is being utilised to enhance the production of biopharmaceuticals in CHO cells.

2:45 Application of 13C Flux Analysis to Identify High-Productivity CHO Metabolic Phenotypes

Jamey_YoungJamey Young, PhD, Associate Professor, Chemical and Biomolecular Engineering, Vanderbilt University

Identifying metabolic phenotypes that promote high expression is a major goal of the biotech industry. We conducted a series of 13C flux analysis studies to examine the metabolic response to IgG expression during early stationary phase of CHO cell cultures. Lactate consumption and citric acid cycle fluxes were most strongly associated with specific IgG productivity. These studies indicate that enhanced oxidative metabolism is a characteristic of high-producing CHO cell lines.

MaxCyte no tagline3:15 Presentation to be Announced

3:45 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 Problem-Solving Breakout Discussions

5:45 Networking Reception in the Exhibit Hall with Poster Viewing

7:00 pm End of Day

5月3日 (木)

8:00 am Morning Coffee

大腸菌

8:30 Chairperson's Remarks

Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH

8:35 Massively Parallel Human Systems Biology in Synthetic Organisms

Jesse_RinehartJesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine

Protein phosphorylation encompasses a central cellular language that determines every facet of normal cellular biology. We have recently created a technology that enables site-specific incorporation of phosphoserine into proteins by expanding the genetic code of Escherichia coli. I will describe our new capability to synthesize and observe phosphoproteome-scale libraries of human phosphoproteins that enable answers to systems level questions regarding the functional role of all human phosphorylation events.

9:05 Evolving and Engineering E. coli Recombinant Protein Production Strains

Jan-Willem_de_GierJan-Willem de Gier, PhD, Professor, Biochemistry and Biophysics, Stockholm University

My laboratory has used both evolutionary and engineering approaches to create E. coli strains with improved properties for recombinant protein production. The evolutionary approaches will be illustrated by the isolation of BL21(DE3)-derived membrane protein production strains. The engineering approaches will be illustrated by the construction of an E. coli strain background with tighter regulation of rhamnose-induced protein production.

 

9:35 Presentation to be Announced


Dyadic9:50 Presentation to be Announced



10:05 Coffee Break in the Exhibit Hall with Poster Viewing

タンパク質発現の新機軸

11:05 RAF1 Kinase: Everything but the Kitchen Sink

William_GilletteWilliam Gillette, PhD, Principal Scientist, Deputy Director, Protein Expression Laboratory, Leidos Biomedical Research, Inc.

RAF1 kinase is a critical protein in the regulation of cell proliferation in normal cells and is the focus of research due to its role in cancer. Obtaining highly purified, active RAF1 in quantities sufficient for HTP assays or structural biological research has not been reported in the literature. I will present a summary of our efforts to express and purify RAF1, and the impact of expression system, cell line, temperature, and length of expression.

11:35 Development-Oriented Biologics Discovery

Jill Carton, PhD, Director, Biologics Discovery, Janssen Biotherapeutics, Janssen R&D

While the biologics market is expanding rapidly with novel and effective therapeutics, the challenges in discovery are steadily increasing. Discovery must be nimble and seamless with development. Recent examples will be discussed that demonstrate Janssen's robust and efficient expression systems to support and profile innovative protein therapeutics that make up the early portfolio.  

12:05 pm Optimisation of Transient Expression Platform to Increase Titre and Throughput

Bernie_SweeneyBernie Sweeney, Senior Group Leader, Mammalian Expression, UCB Pharma


12:35 End of Optimizing Protein Expression

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

カタログダウンロード
カタログ(PDF)